Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02303951 | Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC(NEO-VC) | terminated | Phase 2 | 47 | University Hospital TuebingenOTHER | 2 | Feb 3, 2021 | clinicaltrials |
| NCT03728465 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | terminated | Phase 2 | 6 | University Hospital TuebingenOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01683188 | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma(PROCLIVITY01) | terminated | Phase 4 | 53 | Clinigen, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT00515528 | Vaccination Plus Ontak in Patients With Metastatic Melanoma | terminated | Phase 2 | 17 | University of ChicagoOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT00003509 | Antineoplaston Therapy in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03354962 | Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | terminated | Phase 1 / Phase 2 | 6 | Institut Claudius RegaudOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03241927 | Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | terminated | Phase 2 | 1 | Nina BhardwajOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT01280565 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | terminated | Phase 3 | 134 | AB ScienceINDUSTRY | 7 | Nov 5, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02410863 | Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma(BOTTOM) | terminated | Phase 2 | 10 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00706238 | MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | terminated | Phase 2 | 5 | GlaxoSmithKlineINDUSTRY | 3 | Oct 8, 2020 | clinicaltrials |
| NCT01942993 | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | terminated | Phase 2 | 3 | Philip FriedlanderOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT00505635 | Biochemotherapy With Temozolomide for Metastatic Melanoma | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT03597282 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | terminated | Phase 1 | 22 | BioNTech US Inc.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT03825913 | 3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma | terminated | N/A | 1 | University of MiamiOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT02889861 | IMCgp100-401 Rollover Study | terminated | Phase 2 | 3 | Immunocore LtdINDUSTRY | 2 | Jul 27, 2020 | clinicaltrials |
| NCT02336763 | Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03407170 | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | terminated | Phase 2 | 1 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01324609 | Detection of Choroidal Nevus Cells in Vitrectomy Fluid | terminated | — | 2 | Stanford UniversityOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT00003060 | Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 | 6 | Louisiana State University Health Sciences Center ShreveportOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01308294 | Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients(LAG-3/IMP321) | terminated | Phase 1 / Phase 2 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors(D-1MT) | terminated | Phase 1 | 17 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03674502 | Safety of ADU-1604 in Adults With Metastatic Melanoma | terminated | Phase 1 | 4 | Aduro Biotech, Inc.INDUSTRY | 2 | May 26, 2020 | clinicaltrials |
| NCT03565406 | A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 1 | 11 | NYU Langone HealthOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT02385669 | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma(Mel62; 6PAC) | terminated | Phase 1 / Phase 2 | 3 | Craig L Slingluff, JrOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02718391 | Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.(ACDC) | terminated | Phase 2 | 12 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02968680 | Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma | terminated | Phase 1 | 5 | University of Southern CaliforniaOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01313429 | Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03338777 | Suicide Plus Immune Gene Therapy for Advanced Melanoma(IGTM-101) | terminated | Early Phase 1 | 4 | Hospital Italiano de Buenos AiresOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01557881 | Positron Emission Tomography/Magnetic Resonance Imaging in Patients | terminated | N/A | 98 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT01970527 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 23 | University of WashingtonOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02587650 | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT01437605 | Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03321903 | EPR Tumor Oximetry With CE India Ink | terminated | — | 3 | Philip SchanerOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT01336985 | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads | terminated | Phase 1 | 5 | National Institutes of Health Clinical Center (CC)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03300843 | Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Dec 13, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 3, 2021source: clinicaltrials